Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PlantForm Corp.

Betting a biosimilar antibody made in tobacco can challenge Herceptin

This article was originally published in Start Up

Executive Summary

PlantForm Corp. calls the antibodies it’s producing in tobacco plants “subsequent-entry-biologic” antibody drugs. The first marketed product it hopes to emulate is Roche’s Herceptin. PlantForm’s biosimilar version of Herceptin could come to market years before Roche’s IP is void, because a tobacco-based production method does not infringe on intellectual property covering antibodies made in mammalian cells.



Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts